Saturday 17 October 2026
Export ANTX’s income statement to Excel — free account
AN2 Therapeutics, Inc.
ANTX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 14.3% and free cash flow grew 7.91%, each against the same quarter a year earlier. Dividend growth for three consecutive years; insiders bought in the last twelve months.
3.38
0.22
−6.11%
Follow ANTX
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | 6.88 | 4.87 | 0.87 | 1.01 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | 23.58 | 21.70 | 22.22 | 1.55 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 22 | 36 | 41 | 22 | 21 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | 0.00 | — | — | — | |||||
| EBT | — | — | — | (6) | (14) | (22) | (41) | (65) | (51) | (35) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | (6) | (14) | (22) | (41) | (65) | (51) | (35) | |||||
| Depreciation | — | — | — | — | — | 0 | (1) | (3) | (3) | (1) | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (0.31) | (5.30) | (8.17) | (2.79) | (2.74) | (1.72) | (1.16) | |||||
| Cash flow | — | — | — | (0.13) | (2.09) | (7.76) | (2.18) | (2.26) | (1.65) | (0.99) | |||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | (0.13) | (2.09) | (7.76) | (2.18) | (2.26) | (1.65) | (0.99) | |||||
| Book value | — | — | — | 0.26 | 1.07 | 23.47 | 6.22 | 5.28 | 2.74 | 1.76 | |||||
| Shares, m | — | — | — | 19 | 3 | 3 | 15 | 24 | 30 | 30 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (2) | (5) | (20) | (33) | (53) | (49) | (30) | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | — | (2) | (5) | (20) | (33) | (53) | (49) | (30) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 6 | 3 | 57 | 91 | 96 | 76 | 51 | ||||
| Total debt | — | — | — | — | — | — | 0 | — | — | — | |||||
| Net debt | — | — | — | (6) | (4) | (59) | (96) | (107) | (84) | (58) | |||||
| Shareholders’ equity | — | — | — | 5 | 3 | 62 | 95 | 125 | 82 | 53 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (201.19) | (293.62) | (80.68) | (50.96) | (53.65) | (44.47) | (45.67) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | (402.14) | 0.00 | (250.04) | 0.00 | 0.00 | |||||
| ROE | — | — | — | 43.91 | 111.67 | 82.85 | (178.38) | (58.83) | (49.69) | (52.14) | |||||
Negative figures in brackets.
Charts ten years each
AN2 Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MOLN Molecular Partners AG Sponsored ADR | $143.5M | — (loss-making) | — (loss-making) | −98.86% (below 0%: shrinking) | n/m | +23.77% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TARA Protara Therapeutics, Inc. | $141.8M | — (loss-making) | — | — | n/m | −28.10% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ALXO ALX Oncology Holdings Inc. | $138.3M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | +31.65% (above 0%: growing) | 0.00% | 0.00% | Compare |
| NKTX Nkarta, Inc. | $138.2M | — (loss-making) | — | — | n/m | −29.19% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| AVXL Anavex Life Sciences Corp. | $137.2M | — (loss-making) | — | — | n/m | +27.02% (above 0%: growing) | — | 0.00% | Compare |
| KRRO Korro Bio, Inc. | $137.1M | — (loss-making) | — (loss-making) | −86.28% (below 0%: shrinking) | n/m | +12.07% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ANTX AN2 Therapeutics, Inc. | $135.9M | — (loss-making) | — | — | n/m | +7.91% (above 0%: growing) | 0.00% | 0.00% | |
| CUE Cue Biopharma, Inc. | $135.6M | — (loss-making) | — (loss-making) | +166.66% (above 0%: growing) | n/m | −742.65% (below 0%: shrinking) | 100.00% | (1,113.30%) | Compare |
| TLSA Tiziana Life Sciences Ltd | $134.7M | — (loss-making) | — | — | −258.11% (below 0%: shrinking) | +18.03% (above 0%: growing) | 0.00% | — | Compare |
| Median of peers | $137.7M | — | — | −92.57% | — | +15.05% | 0.00% | 0.00% |
AN2 Therapeutics, Inc. (ANTX) key facts
- AN2 Therapeutics, Inc. (ANTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, ANTX traded at $3.38, a market capitalization of $135.9 million.
- Return on equity was −52.1% and debt-to-equity 0.00.
AN2 Therapeutics, Inc. (ANTX) Latest News
No news at this impact. Lower the threshold for more.